Login to Your Account



Financings Roundup

BioSante Offering to Support Female Sex Dysfunction Drug

By Catherine Shaffer


Monday, March 7, 2011
BioSante Pharmaceuticals Inc. said it will raise $25.1 million in a registered direct offering to support several ongoing clinical trials of its testosterone gel product, Libigel. Pursuant to a prior shelf registration, the Lincolnshire, Ill.-based company will sell 12.2 million shares of common stock and warrants to several institutional investors, with total net proceeds estimated at $23.8 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription